Ionis Pharmaceuticals Reports the Results for Donidalorsen in P-II Trial to Treat Type 1 and Type 2 Hereditary Angioedema
Shots:
- The P-II study evaluated the safety & efficacy of donidalorsen (SC inj. 80mg for Q4W or Q8W & 100mg for Q4W) vs PBO in patients (n=24, aged 18 and above) with Type 1 & 2 hereditary angioedema (HAE) for a duration of 2yrs.
- Patients were eligible to enter the OLE study following a 13wks. blinded study, thereby, of the 20 P-II study participants, 17 entered the OLE study and received a fixed 13wk dosing period of donidalorsen (80mg, Q4W)
- The results from the studies depicted that patients have an overall sustained mean reduction in HAE attack rates of 96% from baseline from 2.70 to 00.6 attack/month along with a clinically meaningful improvement in quality of life measured by AE-QoL for over 2yrs.
Ref: PRNewswire | Image: Ionis
Related News:- Ionis Reports Two-Year P-II OLE Study Results of Donidalorsen for the Treatment of Hereditary Angioedema
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
